Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients [Phase 1]

View source ↗

Summary

A Phase 1 study assessing safety, tolerability, PK and PD of VAY736 in relapsed or refractory chronic lymphocytic leukemia. The study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• VAY736

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | Phase 1 | Status: TERMINATED